Tags

Type your tag names separated by a space and hit enter

The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.
Hum Vaccin Immunother. 2016 07 02; 12(7):1728-37.HV

Abstract

The antibody responses of a reduced-dose intradermal seasonal influenza vaccination have never been studied in COPD patients soon after a pandemic. A total of 149 COPD patients (60 y of age or older) were randomized to receive trivalent influenza vaccine (Sanofi-Pasteur, France) either 9 µg of hemagglutinin (HA) per strain split into 2-site intradermal (ID) injections via the Mantoux technique or one intramuscular (IM) injection of 15 µg of HA per strain. The geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates for influenza A(H3N2) and B administered through the ID injection (n = 75) were similar to those obtained with the IM injection (n = 74) 4 weeks post-vaccination. The antibody responses for influenza A(H1N1)pdm09 administered through the ID injection were lower than those obtained with the IM injection, but all of these responses met the 3 criteria proposed by the Committee for Proprietary Medicinal Products (CPMP) for annual re-licensure. The seroprotection rates 4 weeks post-vaccination for influenza A(H1N1)pdm09 were 64.0% (95%CI 52.7-74.0%) in the ID group vs. 78.4% (95% CI 67.6-86.3%) in the IM group (p = 0.053). Influenza-related acute respiratory illness (ARI), diagnosed as a 4-fold rise in HI titers with a convalescent titer > 1:40, and/or the RT-PCR between the ID group (5.3%) and the IM group (8.1%) were not significantly different. The reduced-dose intradermal influenza vaccine may expand vaccine coverage in cases of vaccine shortage.

Authors+Show Affiliations

a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.b Department of Microbiology ; Siriraj Hospital , Bangkok , Thailand.a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.c Department of Veterinary Pathology , KamphaengSaen , Nakhon Pathom , Thailand.a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27153158

Citation

Chuaychoo, Benjamas, et al. "The Immunogenicity of the Intradermal Injection of Seasonal Trivalent Influenza Vaccine Containing Influenza A(H1N1)pdm09 in COPD Patients Soon After a Pandemic." Human Vaccines & Immunotherapeutics, vol. 12, no. 7, 2016, pp. 1728-37.
Chuaychoo B, Kositanont U, Rittayamai N, et al. The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic. Hum Vaccin Immunother. 2016;12(7):1728-37.
Chuaychoo, B., Kositanont, U., Rittayamai, N., Niyomthong, P., Songserm, T., Maranetra, K. N., Rattanasaengloet, K., & Nana, A. (2016). The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic. Human Vaccines & Immunotherapeutics, 12(7), 1728-37. https://doi.org/10.1080/21645515.2016.1149276
Chuaychoo B, et al. The Immunogenicity of the Intradermal Injection of Seasonal Trivalent Influenza Vaccine Containing Influenza A(H1N1)pdm09 in COPD Patients Soon After a Pandemic. Hum Vaccin Immunother. 2016 07 2;12(7):1728-37. PubMed PMID: 27153158.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic. AU - Chuaychoo,Benjamas, AU - Kositanont,Uraiwan, AU - Rittayamai,Nuttapol, AU - Niyomthong,Parichat, AU - Songserm,Thaweesak, AU - Maranetra,Khun Nanta, AU - Rattanasaengloet,Kanokwan, AU - Nana,Arth, Y1 - 2016/05/06/ PY - 2016/5/7/entrez PY - 2016/5/7/pubmed PY - 2017/10/17/medline KW - COPD KW - acute respiratory illness KW - immunogenicity KW - influenza A(H1N1)pdm09 KW - influenza vaccine KW - intradermal SP - 1728 EP - 37 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 12 IS - 7 N2 - The antibody responses of a reduced-dose intradermal seasonal influenza vaccination have never been studied in COPD patients soon after a pandemic. A total of 149 COPD patients (60 y of age or older) were randomized to receive trivalent influenza vaccine (Sanofi-Pasteur, France) either 9 µg of hemagglutinin (HA) per strain split into 2-site intradermal (ID) injections via the Mantoux technique or one intramuscular (IM) injection of 15 µg of HA per strain. The geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates for influenza A(H3N2) and B administered through the ID injection (n = 75) were similar to those obtained with the IM injection (n = 74) 4 weeks post-vaccination. The antibody responses for influenza A(H1N1)pdm09 administered through the ID injection were lower than those obtained with the IM injection, but all of these responses met the 3 criteria proposed by the Committee for Proprietary Medicinal Products (CPMP) for annual re-licensure. The seroprotection rates 4 weeks post-vaccination for influenza A(H1N1)pdm09 were 64.0% (95%CI 52.7-74.0%) in the ID group vs. 78.4% (95% CI 67.6-86.3%) in the IM group (p = 0.053). Influenza-related acute respiratory illness (ARI), diagnosed as a 4-fold rise in HI titers with a convalescent titer > 1:40, and/or the RT-PCR between the ID group (5.3%) and the IM group (8.1%) were not significantly different. The reduced-dose intradermal influenza vaccine may expand vaccine coverage in cases of vaccine shortage. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/27153158/The_immunogenicity_of_the_intradermal_injection_of_seasonal_trivalent_influenza_vaccine_containing_influenza_A_H1N1_pdm09_in_COPD_patients_soon_after_a_pandemic_ L2 - https://www.tandfonline.com/doi/full/10.1080/21645515.2016.1149276 DB - PRIME DP - Unbound Medicine ER -